BioSpace News Archive

Varian, (NYSE: VAR) today announced the installation of the cyclotron for the Varian ProBeam® Compact single-room proton therapy system at the cancer treatment center on the campus of the Delray Medical Center in Delray Beach, Florida

Creative Medical Technology Holdings, Inc. announced today an update of its activities.

Aetna, one of the leading health care benefits companies in the United States, now covers an additional Abbott neurostimulation technology with a new national coverage policy

New Findings from the Nestlé Feeding Infants and Toddlers Study Underscore Gaps in Food Choices in Young Children’s Diets

SCYNEXIS, Inc., (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the presentation of data at the 2018 European Society of Clinical Microbiology and Infectious Diseases (ESCMID)/American Society for Microbiology (ASM) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Perimenopause--the hormonal “roller-coaster” years preceding menopause--can be a bumpy ride for many women. While symptoms commonly begin around age 42, they can occur earlier or with cancer treatment or hysterectomy. Barb DePree, MD, OB/GYN, Lakeshore Health Partners and Founder of MiddlesexMD, helps women identify early transition signs and prepare for the change of life.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data highlighting the company’s innovative Cloudbreak™ immunotherapy discovery platform will be presented at two upcoming conferences.

Mati Therapeutics Inc. (“Mati”) announced that it has completed a planned interim analysis of an ongoing Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute® sustained ocular drug delivery platform.

Macrolide Pharmaceuticals, which is currently developing novel therapies to fight serious infections, today announced a leadership expansion that adds significant expertise in drug development, clinical strategy, finance and business development to the executive tea

Tempest Therapeutics Inc., a development-stage biotechnology company advancing small molecules that modulate anti-tumor immunity pathways, today announced that Ginna Laport, M.D., joined the company as Chief Medical Officer